IRIS
D'AMICO, EMANUELE
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 3.574
AS - Asia 1.527
EU - Europa 1.474
SA - Sud America 307
AF - Africa 253
OC - Oceania 4
Continente sconosciuto - Info sul continente non disponibili 1
Totale 7.140
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.448
SG - Singapore 765
CN - Cina 548
IE - Irlanda 437
IT - Italia 390
BR - Brasile 274
UA - Ucraina 191
CI - Costa d'Avorio 182
RU - Federazione Russa 122
CA - Canada 114
DE - Germania 93
GB - Regno Unito 53
SN - Senegal 53
IN - India 51
VN - Vietnam 38
FR - Francia 37
KR - Corea 35
SE - Svezia 35
FI - Finlandia 20
BD - Bangladesh 17
NL - Olanda 17
CH - Svizzera 16
PL - Polonia 15
UZ - Uzbekistan 14
AT - Austria 10
EC - Ecuador 8
IQ - Iraq 8
MX - Messico 8
LB - Libano 7
TR - Turchia 7
VE - Venezuela 7
HK - Hong Kong 6
PK - Pakistan 6
AR - Argentina 5
BE - Belgio 5
CZ - Repubblica Ceca 5
GR - Grecia 5
HR - Croazia 5
JP - Giappone 5
LT - Lituania 5
SA - Arabia Saudita 5
ZA - Sudafrica 5
CO - Colombia 4
NG - Nigeria 4
NP - Nepal 4
HU - Ungheria 3
KE - Kenya 3
PE - Perù 3
AU - Australia 2
BO - Bolivia 2
DZ - Algeria 2
ES - Italia 2
IL - Israele 2
LK - Sri Lanka 2
RO - Romania 2
RS - Serbia 2
TN - Tunisia 2
UY - Uruguay 2
AE - Emirati Arabi Uniti 1
AZ - Azerbaigian 1
BA - Bosnia-Erzegovina 1
BG - Bulgaria 1
BT - Bhutan 1
CL - Cile 1
CR - Costa Rica 1
EG - Egitto 1
EU - Europa 1
GT - Guatemala 1
IR - Iran 1
JO - Giordania 1
KH - Cambogia 1
KI - Kiribati 1
LU - Lussemburgo 1
MA - Marocco 1
MD - Moldavia 1
NI - Nicaragua 1
OM - Oman 1
PW - Palau 1
PY - Paraguay 1
SV - El Salvador 1
Totale 7.140
Salva come PNG Salva come JPEG
Città #
Santa Clara 653
Chandler 562
Singapore 463
Dublin 435
Chicago 198
Jacksonville 196
Abidjan 182
Boardman 173
Ashburn 147
Cambridge 119
Lawrence 119
Andover 116
Houston 108
Nanjing 101
Toronto 77
Catania 73
Hefei 68
Beijing 67
Civitanova Marche 63
Des Moines 57
Dakar 53
Wilmington 49
Los Angeles 48
Seoul 35
Nanchang 34
Grafing 33
Shenyang 32
Bremen 31
San Mateo 29
Saint Petersburg 28
Ottawa 27
Dong Ket 26
Council Bluffs 23
Hebei 22
The Dalles 22
Changsha 21
Columbus 21
São Paulo 20
Jiaxing 19
Moscow 16
San Francisco 16
Washington 16
Tianjin 15
Lappeenranta 13
Bari 12
Siracusa 11
Pune 10
Jinan 9
London 9
Norwalk 9
Padova 9
Seattle 9
Zhengzhou 9
Chennai 8
Kunming 8
Mumbai 8
New York 8
Ningbo 8
Ann Arbor 7
Belo Horizonte 7
Dallas 7
Den Haag 7
Hanoi 7
Rio de Janeiro 7
Warsaw 7
Zola Predosa 7
Edinburgh 6
Guangzhou 6
Helsinki 6
Messina 6
Phoenix 6
Porto Alegre 6
Redwood City 6
Rome 6
Amsterdam 5
Brasília 5
Brooklyn 5
Frankfurt Am Main 5
Juiz de Fora 5
Manchester 5
Mascalucia 5
Naples 5
Tashkent 5
Zagreb 5
Brussels 4
Charlotte 4
Civitavecchia 4
Dhaka 4
Goiânia 4
Guarulhos 4
Johannesburg 4
Manfredonia 4
New Delhi 4
Quito 4
Salvador 4
Tokyo 4
Vienna 4
Albinea 3
Baghdad 3
Bernareggio 3
Totale 4.968
Salva come PNG Salva come JPEG
Nome #
Clinical evolution of pure upper motor neuron disease/dysfunction (PUMMD) 129
Global, regional, and national burden of disorders affecting the nervous system, 1990–2021: a systematic analysis for the Global Burden of Disease Study 2021 113
Management of dysphagia in multiple sclerosis: current best practice 112
Comparison of genioglossus muscle activity and efficiency of dexmedetomidine or propofol during drug-induced sleep endoscopy in patients with obstructive sleep apnea/hypopnea syndrome 101
Discontinuation of teriflunomide and dimethyl fumarate in a large Italian multicentre population: a 24-month real-world experience 89
Effectiveness and safety of Rituximab in demyelinating diseases spectrum: An Italian experience 85
Induction therapy for the management of early relapsing forms of multiple sclerosis. A critical opinion 85
Cancer Risk and Multiple Sclerosis: Evidence From a Large Italian Cohort 84
Acetyl-L-Carnitine in Dementia and Other Cognitive Disorders: A Critical Update 84
Can we define a rehabilitation strategy for cognitive impairment in progressive multiple sclerosis? A critical appraisal. 83
Personality Traits and Fatigue in Multiple Sclerosis: A Narrative Review 81
Cognitive dysfunction in multiple sclerosis. A population based study in Catania, Sicily 81
CSF neurotoxic metals/metalloids levels in amyotrophic lateral sclerosis patients: comparison between bulbar and spinal onset 79
Lack of association between Toxocara canis and multiple sclerosis: A population-based case-control study 79
Cognitive impairment and "invisible symptoms" are not associated with CCSVI in MS 77
Association between dietary intake and function in amyotrophic lateral sclerosis 77
Prevalence and Incidence of Multiple Sclerosis in the City of Biancavilla 77
Post-Cerebrovascular Stroke and Early Dysphagia Assessment: A Systematic Review 76
Can new chemical therapies improve the management of multiple sclerosis in children? 75
Lateral switch to IFN beta-1a 44 mcg may be effective as escalation switch to fingolimod in selected persons with relapsing remitting multiple sclerosis: a real-world setting experience 75
Palliative care in progressive multiple sclerosis 74
An update on the safety of treating relapsing-remitting multiple sclerosis 74
Morfometria delle strutture del tronco encefalico in pazienti affetti da atassia spino-cerebellare tipo 2 (SCA 2): indicatore diagnostico e riabilitativo? 74
Approccio clinico e possibilità di trattamento nella SLA 74
Offspring Number Does Not Influence Reaching the Disability's Milestones in Multiple Sclerosis: A Seven-Year Follow-Up Study 73
Exit Strategies in Natalizumab-Treated RRMS at High Risk of Progressive Multifocal Leukoencephalopathy: a Multicentre Comparison Study 73
No evidence of disease activity (NEDA-3) and disability improvement after alemtuzumab treatment for multiple sclerosis: a 36-month real-world study 72
Comparable efficacy and safety of dimethyl fumarate and teriflunomide treatment in Relapsing-Remitting Multiple Sclerosis: an Italian real-word multicenter experience 71
Are oligoclonal bands associated to lower retinal layer thickness at the time of relapsing remitting multiple sclerosis diagnosis? Evidence from an exploratory study 70
Pregnancy outcomes in multiple sclerosis patients previously treated with cyclophosphamide 69
Oral drugs in multiple sclerosis therapy: An overview and a critical appraisal 68
Treatment options of cognitive impairment in multiple sclerosis 67
Familial clustering in Italian progressive-onset and bout-onset multiple sclerosis 67
Validation of the DYMUS questionnaire for the assessment of dysphagia in multiple sclerosis 67
Changes in Anti-JCV Antibody Status in a Large Population of Multiple Sclerosis Patients Treated with Natalizumab 67
Dimethyl fumarate vs Teriflunomide: an Italian time-to-event data analysis 67
Cognitive impairment in clinical isolated syndrome suggestive of multiple sclerosis: association with brain imaging and retinal nerve fiber layer thickness 66
CCSVI and MS. A population-based case-control study in Catania, Sicily. 66
Clinical, laboratory features, and prognostic factors in adult acute transverse myelitis: an Italian multicenter study 66
Late-onset and young-onset relapsing-remitting multiple sclerosis: evidence from a retrospective long-term follow-up study 65
The clinical value of Coop/Wonca charts in assessment of HRQoL in a large cohort of relapsing-remitting multiple sclerosis patients: Results of a multicenter study 64
Detrimental effects of cyclophosphamide on seminal cells in men whith MS 63
Inpatient versus outpatient rehabilitation for multiple sclerosis patients: effects on disability and quality of life 63
Clinical Evolution of Relapsing Remitting Late Onset Multiple Sclerosis: A Nine Year Follow-Up Study 63
Wegener’s Granulomatosis Presenting as An Intracranial Hypertension Syndrome Treated with High Dose of Cyclophosphamide 63
The Neutrophil-to-Lymphocyte Ratio is Related to Disease Activity in Relapsing Remitting Multiple Sclerosis 63
La sindrome disesecutiva nel Mild Cognitive Impairment: aspetti clinici e possibilità riabilitative 63
A critical appraisal of daclizumab use as emerging therapy in multiple sclerosis. 63
Disability may influence patient willingness to partecipate in decision making on first-line therapy in multiple sclerosis 62
Real-life impact of early interferonβ therapy in relapsing multiple sclerosis 62
Personalized Therapy in Multiple Sclerosis: state of art and future perspectives 61
Long term follow-up of combination therapy with inf-eta and cyclophosphamide relapsing-remitting MS patients 61
Neuraxial analgesia is not associated with an increased risk of post-partum relapses in MS 61
Cyclophosphamide induction therapy versus conventional therapy: a pilot study 60
Toxoplasma gondii and multiple sclerosis: a population-based case–control study 60
Treatment-Related Progressive Multifocal Leukoencephalopathy in Multiple Sclerosis: A Comprehensive Review of Current Evidence and Future Needs 59
Primary cerebral vasculitis 59
Placing CD20-targeted B cell depletion in multiple sclerosis therapeutic scenario: Present and future perspectives 59
Pharmacotherapeutic management of lower urinary tract symptoms in Multiple Sclerosis Patients 59
An update on the pharmacological management of pain in patients with multiple sclerosis 59
Metal/metalloid levels in cerebrospinal fluid in the bulbar-and spinal-onset amyotrophic lateral sclerosis 59
Long-term results of immunomodulatory treatment in children and adolescents with multiple sclerosis: the Italian experience 58
Disease trajectory in secondary progressive multiple sclerosis: a ten years follow-up study 58
Clinical perspective on oxidative stress in sporadic amyotrophic lateral sclerosis 58
WII may improve physical abilities in multiple sclerosis: a randomized single blind study 57
Pharmacoeconomics of synthetic therapies for multiple sclerosis 57
Identifying neuropathic pain in patients with multiple sclerosis: a cross-sectional multicenter study using highly specific criteria 57
Immunological Subsets Characterization in Newly Diagnosed Relapsing–Remitting Multiple Sclerosis 57
Mental health status of relapsing-remitting multiple sclerosis Italian patients returning to work soon after the easing of lockdown during COVID-19 pandemic: A monocentric experience 56
Exploring polypharmacy phenomenon in newly diagnosed relapsing–remitting multiple sclerosis: a cohort ambispective single-centre study 55
Depressive symptoms correlate with disability and disease course in multiple sclerosis patients: An Italian multi-center study using the Beck Depression Inventory 55
Gonadal Steroids and Sperm Quality in a Cohort of Relapsing Remitting Multiple Sclerosis: A Case-Control Study 55
Immunosuppression in relapsing remitting multiple sclerosis: moving towards personalized treatment 54
Conventional brain MRI could be a predictor of post partum relapse in multiple sclerosis 53
Pharmacokinetic drug evaluation of daclizumab for the treatment of relapsing-remitting multiple sclerosis 53
To stop or not to stop disease modifying therapies in secondary progressive multiple sclerosis, that is the question 53
Gender related thyroid dysfunction and autoimmunità in multiple sclerosis patients treated with interferon-beta 52
Treatment in worsening multiple sclerosis patients: new drugs are better than older ones? 52
Lateral and escalation therapy in relapsing-remitting multiple sclerosis: a comparative study 52
Genetic burden of common variants in progressive and bout-onset multiple sclerosis 52
A Personalized Approach in Progressive Multiple Sclerosis: The Current Status of Disease Modifying Therapies (DMTs) and Future Perspectives 51
Real-world comparison of Dimethyl-fumarate and teriflunomide in treatment-naive and non responders patients with relapsing remitting multiple sclerosis: preliminary data of a multicenter, prospectie study 51
Could autologous hematopoietic stem cell transplantation be considered a second-line treatment option in relapsing-remitting multiple sclerosis? A critical editorial 51
Untreated relapsing remitting multiple sclerosis (RR-MS) patients. A single centre exprerience 50
The effects of different cognitive and motor tasks on the dual task cost of walking in multiple sclerosis: a case-control study 50
Risk factors in multiple sclerosis: a population-based case-control study in Sicily. Background and methods 50
Negative prognostic impact of MRI spinal lesion in the early stages of relapsing-remitting multiple sclerosis 50
Long-term follow-up of pediatric MS patients starting treatment with injectable first-line agents: A multicentre, Italian, retrospective, observational study 50
Multiple Sclerosis and CCSVI: A Population-Based Case Control Study 49
Hopelessness in Multiple Sclerosis: Psychological and Organic Correlates 47
Use of a low-cost, commercially available gaming console (Nintendo-WII) foe rehabilitation of patients with multiple sclerosis: results of a pilot study 47
Cognitive-motor dual-task interference:A systematic review of neural correlates 47
Serum and CSF N-acetyl aspartate Levels differ in multiple sclerosis and neuromyelitis optica. 47
Pregnancy and the Postpartum Period in Women With Relapsing-Remitting Multiple Sclerosis Treated With Old and New Disease-Modifying Treatments: A Real-World Multicenter Experience 47
Prevalence of pain in multiple sclerosis: a multicenter italian study 46
Is It Time for Ocrelizumab Extended Interval Dosing in Relapsing Remitting MS? Evidence from An Italian Multicenter Experience During the COVID-19 Pandemic 45
The association of CCSVI and MS is not a risk factor for cognitive impariment in MS 45
Real-World comparison of reasons for changing treatment to dimethyl-fymarate or teriflunomide in non responders patients with relapsing remitting multiple sclerosis: preliminary results of a multicenter prospective study 43
Negative prognostic impact of spinal demyelinating lesions at clinical onset in relapsing-remitting multiple sclerosis. 43
Clinical and patient determinants of changing therapy in relapsing-remitting multiple sclerosis (SWITCH study) 42
Totale 6.413
Salva come PNG Salva come JPEG
Categoria #
all - tutte 31.143
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 31.143
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021462 0 36 37 9 166 9 30 5 65 15 47 43
2021/2022799 79 130 15 8 125 4 123 22 52 5 41 195
2022/20231.609 128 84 30 164 154 282 4 281 386 6 68 22
2023/2024704 34 182 37 19 23 119 21 64 4 31 117 53
2024/20252.438 30 366 150 128 493 354 75 94 198 231 172 147
2025/2026462 305 157 0 0 0 0 0 0 0 0 0 0
Totale 7.374